Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Anti-citrullinated protein/peptide antibodies (ACPA) are the principal autoantibody system associated with rheumatoid arthritis (RA), with diagnostic sensitivity of 70% and specificity of 95%. Current testing for ACPA uses the anti-cyclic citrullinated peptide assay (anti-CCP) which measures a generalized reactivity with citrulline-containing peptides, thus giving no insight into reactivity to specific RA antigens. Of these, the best characterized are, α-enolase, fibrinogen/fibrin, vimentin, Type 2 collagen and filaggrin, antibodies to each of which are found in approximately 30-60% of RA cases. Given reports of cross-reactivity between citrullinated antigens, we discuss whether or not measuring these specific antibodies could aid: clinical diagnosis, identification of clinical subsets and drug responses, or provide insight into pathogenic mechanisms or etiology of RA.

Type

Journal article

Journal

Expert review of clinical immunology

Publication Date

12/2013

Volume

9

Pages

1185 - 1192

Addresses

Nuffield Department of Orthopaedics, University of Oxford, Kennedy Institute of Rheumatology, Rheumatology and Musculoskeletal Sciences, Oxford, UK.

Keywords

Animals, Humans, Arthritis, Rheumatoid, Citrulline, Biological Markers, Autoantibodies, Autoantigens, Epitopes, Prognosis, Sensitivity and Specificity, Serology, Cross Reactions, Biomarkers, Pharmacological